Originally published In Press as doi:10.1074/jbc.M200553200 on March 29, 2002
J. Biol. Chem., Vol. 277, Issue 24, 21306-21314, June 14, 2002
Calcium/Calmodulin-dependent Protein Kinase
II
2 and
Isoforms Regulate Potassium Currents of Rat
Brain Capillary Endothelial Cells under Hypoxic Conditions*
Zsolt
Balla
,
Brigitte
Hoch§,
Peter
Karczewski§, and
Ingolf E.
Blasig
¶
From the
Forschungsinstitut für Molekulare
Pharmakologie, Berlin, 13125 Germany and the
§ Max-Delbrück-Center for Molecular Medicine,
Berlin, 13125 Germany
Received for publication, January 18, 2002, and in revised form, March 25, 2002
 |
ABSTRACT |
Endothelial K+ and
Ca2+ homeostasis plays an important role in the regulation
of tissue supply and metabolism under normal and pathological
conditions. However, the exact molecular mechanism of how
Ca2+ is involved in the regulation of K+
homeostasis in capillary endothelial cells, especially under oxidative
stress, is not clear. To reveal Ca2+-triggered pathways,
which modulate K+ homeostasis,
Ca2+/calmodulin-dependent protein kinase II and
voltage-gated outward K+ currents were studied in rat brain
capillary endothelial cells under hypoxia. Whole cell voltage-clamp
measurements showed voltage-gated outward K+ current with
transient and sustained components. mRNA and protein of
Ca2+/calmodulin-dependent protein kinase II
2 and two
isoenzymes were identified. Activation of
the isoforms (autophosphorylation) was typically achieved by the
Ca2+ ionophore ionomycin, which was prevented by the
Ca2+/calmodulin-dependent protein kinase
II-specific inhibitor KN-93. Hypoxia resulted in autophosphorylation of
the
2 and
B isoforms, augmented the
current amplitude, increased the inactivation time constant, and
decreased the extent of inactivation of the transient current. KN-93
prevented both the activation of the isoforms and the alterations in
the K+ current characteristics. It is concluded that the
activation of Ca2+/calmodulin-dependent protein
kinase II decreases inactivation of the voltage-gated outward
K+ current, thereby counteracting depolarization of the
hypoxic endothelium.
 |
INTRODUCTION |
Endothelial cells (EC)1
regulate numerous processes of the vasculature, e.g. blood
coagulation, angiogenesis, barrier, and transport functions. They serve
both as target and release site of vasoactive agents adjusting
circulatory parameters (1). As a primary barrier between circulation
and tissue, they play a major role in the regulation of fluid and
mineral distribution between extravascular and intravascular space.
This is effectively controlled by microvascular EC representing a huge surface.
There is an increasing number of ion channel types revealing different
expression patterns when comparing EC of different origin (1). They
play a role in the regulation of membrane potential (2),
Ca2+-signaling pathways (3), cell volume (4), vessel
permeability (5), and mechanosensor function (6). Although EC are
regarded to be nonexcitable, voltage-gated Ca2+ (7) and
K+ (8) channels have been reported. The channels may be
involved in the release of vasoactive compounds regulated mainly via
intracellular Ca2+ movements. Ion channels are described in
a more detailed manner on macrovascular EC. Little is known about
microvascular EC. The latter express voltage-dependent
Ca2+ (9), Na+ (10), ATP-sensitive (11), and
stretch-sensitive nonselective cation (12) channels. Concerning
K+ channels, Ca2+-activated (13) and
voltage-gated K+ channels (14) have been observed in
microvascular EC.
Ionic and the closely related osmotic homeostasis partly regulated by
ion channels (K+, Na+, Cl
) play
an important role in preserving EC morphology and EC-EC coupling
required for normal vessel permeability (15). Morphological impairment
of EC, such as swelling or EC disorganization, may cause blood flow
disturbances (16) or increased extravasation (17). The tightness of the
blood-brain barrier is greatly affected by hypoxia as indicated by
increased paraendothelial permeability (18) and endothelial swelling
(19). One possible mechanism in endothelial swelling is an alteration
of the K+ channel function, which may result in the loss of
the K+ recycling pathway necessary for a proper
Na+,K+-ATPase function (20).
Members of the diverse superfamily of voltage-activated K+
channels have been demonstrated to be modulated by phosphorylation catalyzed by different protein kinases, among them
Ca2+/calmodulin-dependent protein kinase II
(CaMKII). Phosphorylation of the K+ channel subtype Kv1.4
at the N terminus by CaMKII affects the fast inactivation kinetics and
the current amplitude (21). Modulation of K+ current
inactivation by CaMKII is reported in excitable cells such as atrial
myocytes (22) and colonic smooth muscle cells (23).
CaMKII is a ubiquitously expressed Ser/Thr protein kinase and transmits
Ca2+ signals to a variety of targets ranging from ion
channels to transcription factors. CaMKII is encoded by four separate
genes (
,
,
,
) with partial tissue-specific expression of
its subunits and their numerous splicing variants (24). In the
macrovascular endothelium CaMKII is shown to be involved in the
mechanism of thrombin-induced barrier dysfunction (25), and NO synthase
regulation (26, 27). As intracellular Ca2+ is increased in
EC under pathological conditions, such as hypoxia (28), CaMKII
activation is a potential candidate to be involved in the mechanisms of
such a cell injury.
Here we hypothesize that CaMKII is activated in EC upon oxidative
stress, which in turn modulates K+ channels involved in
maintaining the endothelial supply and barrier function. Therefore, the
aim was to elucidate the effect of hypoxia on CaMKII activity and
K+ current in brain capillary endothelial cells forming the
blood-brain barrier. The presence and activation of various CaMKII
isoenzymes and distinct voltage-gated K+ current components
and their modulation were identified under normal and hypoxic
conditions. Both the K+ current and the CaMKII activation
were sensitive against CaMKII blocker indicating a regulatory relevance
of this pathway for the K+ homeostasis of the microvascular endothelium.
 |
EXPERIMENTAL PROCEDURES |
Chemicals and Antibodies--
Tetraethylammonium-chloride (TEA)
and 4-aminopyridine (4-AP) were from Sigma-Aldrich (Taufkirchen,
Germany). Charybdotoxin was from Alomone Labs (Jerusalem, Israel).
KN-93 water-soluble, KN-92, and ionomycin were from Calbiochem (Bad
Soden, Germany).
To detect CaMKII
, a subclass-specific antibody was used recognizing
isoforms containing the C-terminal second variable domain (29). For
detection of autophosphorylated CaMKII, an antibody was raised in
rabbit against the phosphopeptide MHRQEpTVDC corresponding to
the amino acid sequence surrounding the autophosphorylation site
Thr287 in CaMKII
. The antibody specific for the
-class of CaMKII was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Peroxidase-conjugated anti-rabbit IgG was from
Sigma-Aldrich. The anti-goat IgG conjugated with peroxidase was
obtained from Dianova (Hamburg, Germany). The enhanced
chemiluminescence kit was from Amersham Biosciences. All other reagents
were of analytical grade or better.
Cell Culture--
Immortalized rat brain capillary endothelial
cell line 4 (rBCEC4) (30) was cultured on 10-mm diameter round glass
coverslips (Assistent, Berlin, Germany) covered by rat tail collagen
for electrophysiology or in 6-well plates (BD PharMingen) for RT-PCR and immunoblotting. Cells were grown in Dulbecco's modified Eagle's medium containing 4.5 g/liter glucose, 10% fetal bovine serum, 1.2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin, 100 µg/ml sodium
heparin, 110 µg/ml sodium pyruvate, and 10 µg/ml endothelial cell
growth factor (ECGF). Cultures were maintained in a humidified
atmosphere with 5% CO2 at 37 °C. Medium was changed
each second day. Cells were subcultured weekly from passage 20 to 30. For hypoxia, cells were transferred for 5 h to the Concept Plus
Anaerobic Workstation (Ruskinn Technology Ltd., Leeds, UK) containing a
gas mixture of 90% N2, 5% CO2, and 5%
H2 at 37 °C and 100% humidity (31). For analyzing
CaMKII autophosphorylation after hypoxia, cells were subjected to
normoxic conditions for 30 min up to the fixation to simulate
conditions comparable to those used in the patch-clamp experiments. For
pretreatment, KN-93 or KN-92 was added to the medium 30 min before
starting hypoxia in a quantity to reach a final concentration of 20 µM.
Electrophysiology--
Patch-clamp recordings were performed in
whole cell configuration at room temperature (23 °C). Cells were
transferred from the culture medium into extracellular solution flowing
through a round coverslip recording chamber with a 150-µl volume
(RC-25, Warner Instruments Co., Hamden, CT). Control and test solutions were perfused through the chamber by gravity with an 8-10 ml/h perfusion rate. Clearly separated cells were visually selected for
patch-clamp recording. A digital camera was used to take images.
Patch pipettes without filament (PGL150T-7.5, Harvard Apparatus Ltd.,
UK) were pulled and heat-polished directly before use to a final
resistance of 2-4 megohm. They were coated with monocomponent elastomer. The extracellular solution contained (in mM):
135, NaCl; 5, KCl; 2, CaCl2; 2, MgCl2; 10, Glucose; 10, HEPES; 1, NaH2PO4 (pH 7.4, adjusted with NaOH). In solutions containing higher concentrations of
TEA and 4-AP, Na+ was reduced to maintain constant
osmolarity. The pipette-filling solution contained (in mM):
45, KCl; 100, potassium aspartate; 3, MgCl2; 2, Na2ATP; 10, HEPES; 10, EGTA (pH 7.2, adjusted with KOH).
Whole cell K+ currents were measured by an Axopatch 200A
amplifier (Axon Instruments, Inc.). Clampex 8.1 software (Axon
Instruments, Inc.) was used for command generation and data
acquisition. Currents were digitized at 10 kHz and filtered with
low-pass Bessel characteristics at 5 kHz frequency. Total cell
capacitance and series resistance were calculated and compensated by
adjusting the amplifier's whole cell capacitance and series resistance
(0-85%) compensation controls. Only cells with access resistance of
<10 megohm were accepted for further investigations. Liquid
junction potentials were calculated (
10 to
13 mV), and data were
corrected for each experimental condition.
Voltage-gated outward potassium currents were elicited by step commands
with 1 s duration from
80 to +80 mV in steps of 10 mV preceded
by a 2-s prepulse at
90 mV (Fig. 3, Stimulus). The interstimulus interval was set to 10 s. This stimulus protocol is
suitable to elicit the A-type K+ current. The amplitude of
the sustained current component (Isus) was determined as
the amplitude of the outward current at the end of each trace. The
maximal amplitude of the transient outward current (Ito)
was calculated by subtracting Isus from the peak outward
current (Ipeak). The current amplitudes were normalized to
cell capacitance in each cell.
RT-PCR--
Total RNA from cells was isolated with the Invisorb
system according to the manufacturer's instructions and from rat brain using a guanidine thiocyanate-based method (32). After isolation, remaining DNA contaminations were digested and RNA was re-extracted (29). RT-PCR was performed as described (33). PCR conditions for
amplification of isoforms of the four known CaMKII classes are
described as follows:
and
classes, 3 min, 94 °C denaturation step, 35 cycles (30 s, 94 °C, 30 s, 50 °C, 30 s,
72 °C) of amplification, 5 min, 72 °C final elongation;
-class, 1 min, 95 °C denaturation step, 35 cycles (30 s,
94 °C, 1 min, 55 °C, 1 min, 72 °C) of amplification, 7 min,
72 °C final elongation; and
-class, 3 min, 94 °C denaturation step, 35 cycles (30 s, 94 °C, 1 min, 55 °C, 1 min, 72 °C) of
amplification, 7 min, 72 °C final elongation. Specific primer
combinations for single
isoforms are given in Ref. 29. Transcript
patterns of the other classes (
,
,
) were investigated using
primer pairs flanking the variable regions of the corresponding class. Therefore, all expressed variants of these classes should be amplified. The forward and reverse sequences of
-class-specific primers containing a flanking EcoRI site were as follows: GCG GAA
TTC AAG AAT GAT GGC GTG AAG GAA and GCG GAA TTC ACC CTG GCC TGG TCC TTC
AAT (accession no. J02942), for the
-class GAC AGG AGA CTG TGG AAT
GTC TGA AGA and AGT CCC CAT TGT TGA CGG CCT CAA TGA (accession no.
M16112), and for the
-class GCC AAG AGA CAG TGG AGT GCT TAC GCA and
CAG CGG TGC AGC AGG GGC TCC TGA GCA GTG ATA (accession no. J04063). PCR
products were analyzed with ethidium bromide-stained 2% agarose gels
or 4% native polyacrylamide gels. For sequencing, amplification
products were extracted from gels, and standard cycle sequencing
reactions were performed commercially by InViTek (Berlin-Buch, Germany).
Preparation of Cell Lysates and Immunoblotting--
Cell
cultures were washed with HEPES-buffered Hanks balanced salt solution
and incubated for 15 min at 37 °C for stabilization. 250 nM ionomycin was used for activation of CaMKII. For
inhibition of CaMKII, cells were preincubated with 20 µM
KN-93 for 30 min before the addition of ionomycin. Cells were fixed by
the addition of ice-cold trichloroacetic acid to a final concentration
of 5% and immediately placed on ice. They were washed twice with
ice-cold 2.5% trichloroacetic acid and harvested. The precipitates
were centrifuged at 12,000 × g at 4 °C for 10 min.
The supernatant was aspirated, and the pellets were dissolved in
electrophoresis sample buffer at pH 6.8, neutralized if necessary with
1 M Tris, and heated at 95 °C for 5 min. Electrophoretic
separation on 10% SDS-polyacrylamide gels and immunoblotting were
performed as described in Ref. 29 with 20 µg of cell protein per
lane. The autophosphorylated CaMKII-specific antibody was used in a
final concentration of 1 µg/ml. The antibodies obtained from
commercial sources were used according to the manufacturer's
instructions. Visualization of the immunoreaction was by enhanced
chemiluminescence kit and autoradiography on x-ray film. Protein was
measured in cell soluble lysates by a modified Lowry method
(34).
Data Analysis--
Clampfit 8.1 software (Axon Instruments,
Inc.) was used for off-line raw data analysis. Further data processing
and analysis was performed by MicrocalTM Origin® software
(Microcal Software, Inc.). Two-dimensional area measurement of digital
images of cultured cells was made by Scion Image for Windows software
(Scion Corp., Frederick, MD). The time constant of the fast
inactivation phase (
fast) of the transient current was
calculated by biexponential fitting on the decay phase of the outward
current. The extent of inactivation was determined as the contribution
of the transient outward current to the total peak current
(Ito/Ipeak). Values are presented as mean ± S.E. To reveal the significance of differences, paired or unpaired Student's t tests were used with significance defined as:
*, p < 0.05; **, p < 0.01.
 |
RESULTS |
Swelling of Hypoxic Cells--
Micrographs (Fig.
1) show the same cultured cells before
and after the hypoxia protocol. Arrows indicate the regions
of apparent swelling. The surface area of the cells subjected to 5 h of hypoxia showed a significant increase compared with the initial
values measured before the initiation of hypoxia protocol, whereas in the case of the control cell group, which was measured after the same
period without hypoxia, no significant increase was seen. (See Fig. 1;
initial value, 481 ± 23 µm2, n = 29; control value, 510 ± 37 µm2, n = 20; hypoxic value, 617 ± 36 µm2,
n = 21, p < 0.05 compared with the
initial value.) These results suggest that hypoxia caused a significant
increase of the cell volume (swelling).

View larger version (66K):
[in this window]
[in a new window]
|
Fig. 1.
Swelling of rat brain capillary endothelial
cells after hypoxia. Phase contrast light microscopic digital
images (×40). Cells subjected to 5 h of hypoxia displayed
significant swelling during reperfusion (see arrows)
compared with the initial untreated state. The diagram
represents the cell surface area of the initial, control, and hypoxic
cell groups. The hypoxic group showed a significant increase of cell
surface area in contrast to the control group. Both groups were
compared with the initial (preincubation) period. Mean ± S.E. *,
p < 0.05 compared with the initial value.
|
|
Components of the Voltage-gated Outward Potassium Current and Their
Selectivity--
To reveal possible pathways involved in the
adaptation to swelling and Ca2+ overload caused by hypoxia
of rBCEC4, voltage-gated outward potassium currents were investigated.
Two different components of the total outward current were identified,
a transient outward component (Ito) with fast activation
and rapid inactivation and a sustained component (Isus)
that showed no inactivation within the period of stimulus waveform (see
"Experimental Procedures").
Different potassium channel blockers were used for pharmacological
characterization of the outward current components. 4-AP and TEA showed
a dose-dependent inhibitory effect on current amplitudes (Fig. 2, A and B).
The inhibition revealed different characteristics as presented by a
sigmoidal fit to the plots of normalized current values against the
concentration of 4-AP (Fig. 2C) and TEA (Fig. 2D). 4-AP blocked Ito with a half-maximal
inhibitory concentration (IC50) of 1.1 ± 0.04 mM. The Hill coefficient was 2.9 ± 0.05 (n = 3). 4-AP inhibition reached a maximal effect at 5 mM, which decreased the current amplitude to 9% compared
with control values of +70 mV (Fig. 2C). Similar values for
the 4-AP effect were reported earlier in EC (13) and myocytes (35). TEA
inhibited Isus with an IC50 value of 2.8 ± 0.5 mM and a Hill coefficient of 1.4 ± 0.3 (n = 3). 10 mM TEA reached maximal blocking
effect and reduced Isus to 21% of the control amplitude at
+70 mV (Fig. 2D). Comparable values of TEA inhibition were
observed in EC (13, 14) and neurons (36). 1 µM
charybdotoxin, an inhibitor of Ca2+-activated
K+ current, did not influence Ito and
Isus significantly (not shown).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
The inhibitory effect of potassium channel
blockers on outward K+ current components of rBCEC4.
Currents were elicited as shown in Fig. 3, Stimulus
panel. The amplitude of the sustained current component
(Isus) was determined as the amplitude of the outward
current at the end of each trace. The maximal amplitude of the
transient current (Ito) was calculated by subtracting
Isus from the peak outward current (Ipeak).
Current amplitudes were normalized to cell capacitances.
Current-voltage curves demonstrate the effect of increasing
concentrations of 4-AP on Ito (A) and TEA on
Isus (B). Current amplitudes registered at +70
mV were normalized to the control (Icont) current amplitude
and plotted against the concentration of 4-AP (C) and TEA
(D).
|
|
Hypoxia Increased the Amplitude of Voltage-gated Outward Potassium
Current Components, and KN-93 Impeded the Effect of Hypoxia--
To
focus on Ca2+-triggered pathways, which may modulate
K+ homeostasis, one group of cells was pretreated with
KN-93 before the hypoxia protocol. Registrations were made under
control conditions (Fig. 3A),
after hypoxia (Fig. 3B), and after hypoxia preceded by KN-93
application (Fig. 3C). The current-voltage (I-V)
relationship of Ito and Isus (Fig. 3,
D and E) were calculated in each experimental condition mentioned above. In cells subjected to hypoxia the amplitudes of both Ito and Isus were elevated
(Ito at +70 mV, 11.5 ± 2.3 pA/pF, n = 22 in control group versus 15.9 ± 1 pA/pF,
n = 16 in hypoxic group, p < 0.05;
Isus at +70 mV, 11.4 ± 2.4 pA/pF, n = 23 in control group versus 24.1 ± 4.9 pA/pF,
n = 18 in hypoxic group, p < 0.01). In
cells pretreated with KN-93 Ito and Isus were
in the range of the controls (Ito at +70 mV, 10.7 ± 1.7 pA/pF, n = 16, Isus at +70 mV,
10.3 ± 2.4 pA/pF, n = 17).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 3.
The effect of 5 h of hypoxia on
potassium current amplitudes in the presence and absence of 20 µM KN-93 added 30 min before hypoxia in
rBCEC4. Recordings were obtained in whole cell configuration.
Outward current traces were elicited from a holding potential of 90
mV by voltage steps from 80 to +80 mV in steps of 10 mV with a 1-s
duration (Stimulus). The current amplitudes were normalized
to cell capacitance in each cell. Registrations were made under control
conditions (A), after hypoxia (B), and after
hypoxia preceded by KN-93 application (C). D,
current-voltage (I-V) relationship of the transient current in control
condition ( ) (n = 22), after hypoxia ( )
(n = 16), and after hypoxia preceded by KN-93
application ( ) (n = 16). E, I-V
relationship of the sustained current in control condition ( )
(n = 23), after hypoxia ( ) (n = 18),
and after hypoxia preceded by KN-93 application ( )
(n = 17). Mean ± S.E. *, p < 0.05, **, p < 0.01 compared with the respective
control.
|
|
KN-92, the inactive analogue of KN-93, was used by the same application
protocol as a negative control to reveal that the effect of KN-93 could
be related to CaMKII inhibition and not to a direct modulatory effect
on K+ channels. KN-92 did not affect the hypoxia-induced
elevation of the amplitude of Ito (at +70 mV, 15.6 ± 1.5 pA/pF, n = 11) and Isus (at +70 mV,
23.7 ± 8.8 pA/pF, n = 11).
Inactivation of Ito Decreases after Hypoxia, and the
Effect of Hypoxia Is Prevented by KN-93--
fast, the
time constant of the fast inactivation phase of Ito (see
"Experimental Procedures") showed voltage dependence in the +10 to
+80 mV voltage range under all experimental conditions (Fig.
4B). Traces shown in Fig.
4A were recorded at +70 mV holding command (Fig. 4,
Stimulus) under control conditions and 5 h after hypoxia alone and preceded by KN-93 administration.
fast
elevated significantly after 5 h of hypoxia indicating the slower
inactivation of Ito (control group at +70 mV, 76.7 ± 2.5 ms, n = 21 versus hypoxic group at
89.7 ± 3.2 ms, n = 16, p < 0.01). A previous application of KN-93 prevented the effect of hypoxia
on
fast (at +70 mV, 71.6 ± 2.6 ms,
n = 15) (Fig. 4B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 4.
The effect of 5 h of hypoxia on
fast and
Ito/Ipeak in the presence and absence of
20 µM KN-93 added 30 min before
hypoxia in rBCEC4. A, superimposition of original
current traces recorded at +70 mV holding command (Stimulus)
under control conditions and 5 h after hypoxia alone and with
KN-93 pretreatment. B, fast, the time
constant of the fast inactivation phase of Ito, which was
derived by biexponential fitting on the decay phase of the transient
outward current, was plotted against holding command values under
control conditions ( ) (n = 21), after 5 h of
hypoxia alone ( ) (n = 16), and with KN-93
pretreatment ( ) (n = 15). C, the extent
of inactivation expressed as the contribution of the transient outward
current to the total peak current (Ito/Ipeak)
is displayed under the control condition (n = 22),
after 5 h of hypoxia alone (n = 16), and preceded
by KN-93 treatment (n = 15). Mean ± S.E. *,
p < 0.05; **, p < 0.01 compared with
the respective control.
|
|
The Ito/Ipeak ratio, which describes the extent
of inactivation (see "Experimental Procedures"), decreased
significantly after hypoxia, pointing to a decreased contribution of
Ito to the total current (control group, 0.5 ± 0.04, n = 22 versus hypoxic group, 0.4 ± 0.02, n = 16, p < 0.01). In the group
subjected to KN-93 application before hypoxia, the
Ito/Ipeak value was in the control range (at
+70 mV, 0.51 ± 0.04, n = 15) (Fig.
4C).
Pretreatment of the cells with KN-92 before hypoxia did not impeded the
alteration of the
fast value (at +70 mV, 93.4 ± 4.9 ms, n = 11) and the
Ito/Ipeak ratio (at +70 mV, 0.4 ± 0.06, n = 11).
mRNA Expression of CaMKII Isoenzymes in rBCEC4 Cells--
To
assess the expression pattern of CaMKII in rBCEC4, we determined the
mRNA transcript pattern by RT-PCR and immunoblotting with class- or
isoform-specific primer combinations (Fig.
5). The class-specific primers for
,
, and
isoforms of CaMKII were derived from the conserved domains
of these classes flanking their variable parts. Therefore, all
expressed isoforms of these classes should be detected. For
-CaMKII,
primers specific for individual isoforms of this class were used. Since
- and
-CaMKII are known to be neuronally expressed (37), RNA from
rat brain was amplified in parallel as a positive control. As expected, no
- and
-CaMKII-specific signals were obtained in rBCEC4 cells, whereas products of the expected sizes were amplified from the brain
RNA fraction (Fig. 5, upper left and upper
middle). With the
-class-specific combination, two products
were detected in rBCEC4-derived preparations that were identified by
size or by sequencing as isoforms
B and
C
(38) (Fig. 5, upper right).
-CaMKII is characterized by
the appearance of a second C-terminal variable domain (39). To assess
the transcript pattern of CaMKII
in rBCEC4 we concentrated on the
non-neuronal members of this subclass (isoforms
2,
3,
4,
9) (29). As shown in
the lower part of Fig. 5, rBCEC4 expressed only transcripts for isoform
2. The very faint band arising in
4-specific amplification reactions is not close to the
size of the positive control obtained with the
4-containing plasmids (530 bp, positive
control). Therefore, it was considered to be an artifact of the
PCR.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 5.
mRNA expression of CaMKII isoenzymes in
rBCEC4 cells. RT-PCR signals after 35 cycles of amplification
derived from total RNA preparations of rBCEC4 cells (1) and rat brain
(3) with primer combinations specific for CaMKII classes (upper left), (upper middle), (upper right), and for individual members of the -CaMKII
class (lower). As a negative control, RT-PCR of rBCEC4 RNA
in the absence of reverse transcriptase was carried out (2). Where
indicated, control PCR with plasmids containing the corresponding
isoforms was done in parallel (positive control). Sequencing
of the corresponding signal revealed the identity of a -derived
rBCEC4 product as an artifact (unspecific). For -, -,
and -CaMKII 2% agarose gels and for the separation of the
-CaMKII products, a 4% native polyacrylamide gel were used. Base
pair (bp) values represent the bands of the respective
standard samples. Arrows indicate the size (bp)
of the detected signal.
|
|
Protein Expression of CaMKII in rBCEC4--
To analyze the
expressed proteins of CaMKII in rBCEC4 based on the mRNA data,
CaMKII
- and CaMKII
-specific antibodies were employed. The
-specific antibody specifically recognizes isoforms with the unique
C-terminal extension that comprises a subset of the CaMKII
isoforms
known at present (29). The
-specific antibody is directed against an
amino acid sequence conserved in all known
isoforms, and thus is
able to detect all forms of CaMKII
. Fig. 6A shows immunoblots with
extracts of rBCEC4. The
-specific antibody exclusively
detects a signal at about 54 kDa (lane 1). Based on our
transcript data and the apparent molecular mass, this protein may be
attributed to the CaMKII isoform
2. The
-specific
antibody produces three reactive bands at about 60, 54, and 42 kDa. The prominent protein band at 60 kDa correlates with the deduced molecular mass of CaMKII
B, and according to our mRNA data it
most likely represents the isoform
B. The very faint
54-kDa band, migrating exactly at the position of
2,
coincides in size with the deduced molecular mass of isoform
C. However, we cannot exclude the possibility that the
signal is produced by a cross-reaction of the antibody with
CaMKII
2. The nature of the prominent immunoreactive
protein band at about 42 kDa remains to be identified. It is not in the size range of any known CaMKII protein.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 6.
Protein expression and activation of CaMKII
isoenzymes in rBCEC4. A, expression of CaMKII protein.
Lane 1 shows the immunoreactivity obtained with the
CaMKII -specific antibody, lane 2 gives the reaction with
the CaMKII -specific antibody. B, autophosphorylation of
CaMKII and isoforms in rBCEC4 by the addition of ionomycin
without and after 30 min of preincubation with KN-93 (20 µM). c, control: iono, ionomycin
(250 nM). The arrows indicate the positions of
approximately 54 kDa for CaMKII and 60 kDa for CaMKII obtained
with the antibody directed against the autophosphorylated forms of
CaMKII. MM is molecular mass.
|
|
Activation of CaMKII Isoforms in
rBCEC4--
CaMKII
2 and CaMKII
became
autophosphorylated when rBCEC4 were subjected to ionomycin. At a
concentration of 250 nM ionomycin leads to the detection of
two protein bands by the CaMKII autophosphorylation site-specific
antibodies, corresponding to the positions of CaMKII
2 (54 kDa) and CaMKII
B (60 kDa). The autophosphorylation
of the 54-kDa protein was very low in controls and increased quickly and transiently in response to ionomycin with the maximum of 30 s.
It was not detectable anymore at 10 min. In contrast, the 60-kDa protein showed an apparent higher basal level of autophosphorylation that increased more slowly after ionomycin application and remained stable for at least 10 min. Interestingly, there was no
autophosphorylation-specific reaction at the position of 42 kDa,
supporting our assumption that the protein detected by anti-CaMKII
does not represent a functional CaMKII isoform. A 30-min pretreatment
with 20 µM KN-93 reduced the autophosphorylation of both
isoenzymes considerably (Fig. 6B).
Effect of Hypoxia on CaMKII Autophosphorylation in
rBCEC4--
Hypoxia resulted in activation of CaMKII in
rBCEC4 as demonstrated by autophosphorylation of both
CaMKII
2 and CaMKII
(Fig. 7A). In controls there was
only very low autophosphorylation detectable for
2,
which increased significantly because of hypoxia (control, 10 ± 2.6 OD, n = 3 versus hypoxia, 85.6 ± 7.4 OD, n = 5, p < 0.01) (Fig.
7B). In control cells
B elicits a higher
autophosphorylation than
2 resulting in hypoxia-treated
cells in a higher maximum. However, the cells show a smaller
increment of autophosphorylation compared with that of
2. The increase in autophosphorylation of the
B isoenzymes was about 60% and statistically
significant (control, 74.3 ± 5.7 OD, n = 3 versus hypoxia, 121.8 ± 10.7 OD, n = 5, p < 0.05). The CaMKII inhibitor KN-93 completely
abolished the response in autophosphorylation to hypoxia for both
CaMKII
2 (11.6 ± 1.6 OD, n = 5) and
CaMKII
(75.6 ± 9.9 OD, n = 5).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of 5 h of hypoxia of rBCEC4 on
autophosphorylation of CaMKII isoenzymes in the absence and presence of
KN-93. Control cultures (sample 1), hypoxic cultivated
cells (sample 2), and hypoxic cultivated cells in the
presence of 20 µM KN-93 (sample 3).
A, immunoblot with the respective autophosphorylation
site-specific antibodies (P-CaMKII , P-CaMKII ). B,
quantification of optical density of the immunoblots in 3-5 individual
culture dishes of each experimental group. MM is molecular
mass. Mean ± S.E. *, p < 0.05; **,
p < 0.01, compared with the respective control.
|
|
 |
DISCUSSION |
The current study for the first time provides evidence for a role
of CaMKII in the regulation of voltage-gated K+ channels in
hypoxic rat brain capillary endothelial cells. A function of the CaMKII
has been described in macrovascular endothelial cells but not in the
widely differentiated microvasculature that is specialized depending on
surrounding tissue. In aortic endothelial cells, CaMKII can be involved
in the response to oxidative stress caused by
H2O2 (26) or in thrombin-induced cytoskeletal
reorganization and endothelial barrier dysfunction (25). The isoenzyme
pattern of CaMKII in the endothelium is unknown. In this study the
presence of CaMKII
2 and CaMKII
is demonstrated in
brain capillary endothelial cells, and evidence is presented for their
functional coupling to voltage-gated K+ currents under
hypoxic conditions. Hypoxia increases the intraendothelial free
Ca2+ concentration as shown earlier (28). The isoenzymes
identified in rBCEC4 are activated (autophosphorylated) in a
Ca2+-dependent manner by hypoxia. The
autophosphorylation and the alteration of the K+ current
characteristics, both caused by hypoxia, are prevented by the selective
CaMKII inhibitor KN-93.
The function of the outward voltage-gated K+ current
measured in the brain capillary endothelial cells used in the current study is probably related to the regulation of membrane potential. K+ channels are involved in membrane potential regulation
in depolarized cells, and they can counteract further membrane
depolarization (14). This may possess a regulatory function during
membrane potential oscillations elicited by vasoactive agonists (40) or
during membrane depolarization caused by oxidative stress (41). Regulation of membrane potential plays a pivotal role in
Ca2+ homeostasis since voltage-gated Ca2+
channels serve as one possible pathway for Ca2+ influx
(42).
In rBCEC4 we found a transient and a sustained K+ current
component. The characteristics of the transient current corresponds to
the A-type, a fast-activating and fast-inactivating outward voltage-gated K+ current. To the sustained component, a
delayed rectifier current contributes to a great extent as demonstrated
by the effect of TEA. Both the A-type and the delayed rectifier current
are reported to be present in primary capillary endothelial cells (13,
14). This means that rBCEC4 preserves primary properties, making them suitable for further electrophysiological studies. Moreover, the action
of the specific K+ channel blockers 4-AP and TEA suggests
that the majority of the outward current is carried by K+.
Finally, the absence of a charybdotoxin effect indicates that Ca2+-activated K+ channels are not directly
involved in the modulation of the voltage-gated K+ current
components investigated.
Upon hypoxia, rBCEC4 shows an increased
value and a reduced
Ito/Ipeak ratio, indicating a decrease of the
transient current inactivation that leads to elevation of the transient
and sustained K+ current components. A similar change in
K+ currents has been observed in myocytes dialyzed with
autophosphorylated CaMKII (23). The hypoxia-related rise in the
value, the diminished Ito/Ipeak ratio, and the
elevated transient and sustained K+ current amplitudes can
be prevented by the specific CaMKII inhibitor KN-93. Taken together,
the assumption is supported that CaMKII enhances the release of
K+ from hypoxic rBCEC4 when voltage-gated K+
channels are operating.
Immunohistochemistry experiments reveal an expression of
Kv1.4 channels in rBCEC4 (data not shown). These channels are rapidly inactivated via their N-terminal inactivation domain (43). In human
embryonic kidney (HEK) cells, phosphorylation of the N-terminal part of
the transfected Kv1.4 channel by CaMKII decelerates the inactivation of
the fast-inactivating A-type current (21). Therefore, it is proposed
that CaMKII regulates the inactivation of the K+ current in
rBCEC4. This conclusion is supported by a considerable deceleration of
the transient current inactivation under hypoxic conditions when the
detected CaMKII isoenzymes were activated. It is known that
voltage-gated K+ channels can be modulated by
serine/threonine phosphorylation regulated by Ca2+ (44).
CaMKII is such a Ca2+-dependent
serine/threonine protein kinase (24). The assumption of a
CaMKII-regulated K+ current is further supported by using
the CaMKII inhibitor KN-93, which inhibits the activation of CaMKII and
prevents the decrease of the inactivation of the K+ current
in our experiments. Up to now, CaMKII-regulated K+ channels
have not been reported in nonexcitable cells. In myocytes the
regulation of a transient A-type K+ current by
CaMKII is described under control conditions that are sensitive to
KN-93 (22, 23). To our knowledge, a function of CaMKII has not yet been
known for disturbances caused by oxidative stress.
Beside its specific CaMKII inhibitory effect, KN-93 can exert a
nonspecific action on K+ currents directly blocking
K+ channels. In rabbit smooth muscle cells KN-93 blocks the
voltage-dependent K+ current significantly and
dose dependently in a manner that is similar to its non-CaMKII
inhibiting analogue KN-92 (45). In our experiments the action of KN-93
was specific; its effect was confined to CaMKII inhibition only. This
is confirmed since KN-92 has no effect on
and
Ito/Ipeak value or the current amplitudes under
hypoxic conditions.
After hypoxia we have found a significant cell swelling that is a
typical sign of hypoxic cell injury (19). Activation of the CaMKII
isoenzymes observed in parallel reflects enhanced intracellular Ca2+ concentration. The hypoxic increase of cytosolic
Ca2+ and the hypoxic cell swelling are well described in
endothelial cells (28). Hypoxia experiments on cultured human
endothelial cells give evidence that the Ca2+ uptake is
mainly due to the influx of extracellular Ca2+ (46).
Cellular Ca2+ accumulation is known to be related to
morphological changes. Laser scanning microscopic studies revealed that
bleb formation induced by hypoxic stress involves regional elevation of
Ca2+ in human umbilical vein endothelial cells (47). In
addition, hypoxia impairs the blood-brain barrier function of brain
endothelial cells as indicated by increased paraendothelial
permeability (18). In our investigation hypoxia conditions (18, 28)
that are proven to elevate the cytosolic concentration of
Ca2+ (28) necessary to intensify the activation of CaMKII
were used.
As we show here for the first time, brain capillary endothelial cells
express non-neuronal members of the CaMKII
and CaMKII
classes at
both the transcript and protein levels. There are no transcripts
of the primarily neuronally expressed
and
subunits of CaMKII
(24) that are detectable. From the known CaMKII
isoenzymes being
prominently expressed in non-neuronal excitable tissue, only
2 is detected in rBCEC4.
2 is
ubiquitously expressed in cells of peripheral tissues and represents a
constitutively expressed isoform in the heart (29, 48, 49). Transcripts
of two isoenzymes of CaMKII
are identified in rBCEC4. Immunoblot
experiments give evidence that
B protein is expressed,
whereas a faint band is consistent in size with the predicted molecular
mass of
C but may also result from a cross-reaction with
the highly expressed
2 protein.
B has
been demonstrated to elicit higher total as well as autonomous
autophosphorylation-dependent catalytic activity than
C (50). Thus, our data suggest that
B is
the dominant isoform of the CaMKII
class in brain capillary
endothelial cells.
In response to the elevation of intracellular Ca2+ by
treatment with ionomycin, as demonstrated in rBCEC4,
2
shows a more rapid activation in terms of autophosphorylation compared
with CaMKII
B. Autophosphorylation of
B
in response to ionomycin occurs more slowly but remains at plateau
levels, whereas
2 is rapidly dephosphorylated. This
different time course of activation can be due to differences in the
accessibility of activating Ca2+ and/or calmodulin,
e.g. by distinct intracellular localization of the
isoenzymes, different phosphatase action, or specific properties of
individual CaMKII isoforms. It has been shown that
B
needs higher concentrations of calmodulin for activation, but
B binds calmodulin more tightly than other CaMKII
isoforms (51). However, kinetic properties of members of the CaMKII
class have not yet been investigated. After hypoxic treatment of rBCEC4
autophosphorylation of both
2 and
B is
found to be significantly elevated. The response to hypoxia appears to
be more pronounced for
2. Previous findings on a rat
myoblast cell line show that
2 also localizes to the plasma membrane (29). This supports the notion that
2
may be involved in the modulation of K+ channel properties
in rBCEC. The autophosphorylation of CaMKII persisted after hypoxia for
a longer time. Thus, CaMKII remains activated during measurement of the
K+ current, and it is most likely that the hypoxia-induced
changes of K+ channel properties are caused by CaMKII activation.
In conclusion, one can state that because of hypoxic ATP
reduction (19), elevation of cytoplasmic Ca2+ level (28)
results in the activation of CaMKII
2, which is thought
to be mainly responsible for decreasing the inactivation of the outward
K+ current. Our results concerning the increased outward
K+ current mediated by the activation of CaMKII support the
hypothesis that this pathway may augment the counteracting regulatory
effect against depolarization caused by hypoxia.
Acknowledgments--
We thank Barbara Eilemann for cultivation of
the cells and Dorothea Riege and Ingrid Ameln for expert technical assistance.
 |
FOOTNOTES |
*
This work was supported in part by Grants
Sonderforschungsbereich 507 TP A2, Deutsche Forschungsgemeinschaft GK
238-2, BL 308/6-1, Bundesministerium für Bildung, Wissenschaft,
Forschung und Technologie BEO 0311466C (to I. B.), and Kra 1330/3-2
from the Deutsche Forschungsgemeinshaft (to P. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Forschungsinstitut
für Molekulare Pharmakologie, Robert-Rössle-Str. 10, 13125 Berlin, Germany. Tel.: 49 30 94793-244; Fax: 49 30 94793-243; E-mail: iblasig@fmp-berlin.de.
Published, JBC Papers in Press, March 29, 2002, DOI 10.1074/jbc.M200553200
 |
ABBREVIATIONS |
The abbreviations used are:
EC, endothelial
cells;
CaMKII, Ca2+/calmodulin-dependent
protein kinase II;
rBCEC4, rat brain capillary endothelial cell line 4;
TEA, tetraethylammonium chloride;
4-AP, 4-aminopyridine;
Ito, transient outward current;
Isus, sustained
outward current;
Ipeak, peak outward current;
RT-PCR, reverse transcriptase-PCR.
 |
REFERENCES |
| 1.
|
Nilius, B.,
Viana, F.,
and Droogmans, G.
(1997)
Annu. Rev. Physiol.
59,
145-170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Daut, J.,
Standen, N. B.,
and Nelson, M. T.
(1994)
J. Cardiovasc. Electrophysiol.
5,
154-181[Medline]
[Order article via Infotrieve]
|
| 3.
|
Busse, R.,
Mulsch, A.,
Fleming, I.,
and Hecker, M.
(1993)
Circulation
87,
18-25
|
| 4.
|
Nilius, B.,
Oike, M.,
Zahradnik, I.,
and Droogmans, G.
(1994)
J. Gen. Physiol.
103,
787-805[Abstract/Free Full Text]
|
| 5.
|
He, P.,
and Curry, F. E.
(1991)
Am. J. Physiol.
261,
H1246-1254[Medline]
[Order article via Infotrieve]
|
| 6.
|
Lansman, J. B.,
Hallam, T. J.,
and Rink, T. J.
(1987)
Nature
325,
811-813[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Bkaily, G.,
d'Orleans-Juste, P.,
Naik, R.,
Perodin, J.,
Stankova, J.,
Abdulnour, E.,
and Rola-Pleszczynski, M.
(1993)
Br. J. Pharmacol.
110,
519-520[Medline]
[Order article via Infotrieve]
|
| 8.
|
Takeda, K.,
Schini, V.,
and Stoeckel, H.
(1987)
Eur. J. Physiol. (Pfluegers Arch.)
410,
385-393
|
| 9.
|
Bossu, J. L.,
Elhamdani, A.,
and Feltz, A.
(1992)
FEBS Lett.
299,
239-242[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Walsh, K. B.,
Wolf, M. B.,
and Fan, J.
(1998)
Am. J. Physiol.
274,
H506-512[Medline]
[Order article via Infotrieve]
|
| 11.
|
Popp, R.,
and Gogelein, H.
(1992)
Biochim. Biophys. Acta
1108,
59-66[Medline]
[Order article via Infotrieve]
|
| 12.
| Popp, R., Hoyer, J., Meyer, J., Galla, H. J., and Gogelein, H. (1992) J. Physiol. 454435-454449
|
| 13.
|
Jow, F.,
Sullivan, K.,
Sokol, P.,
and Numann, R.
(1999)
J. Membr. Biol.
167,
53-64[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Dittrich, M.,
and Daut, J.
(1999)
J. Physiol.
277,
H119-127
|
| 15.
|
Dejana, E.,
Corada, M.,
and Lampugnani, M. G.
(1995)
FASEB J.
9,
910-918[Abstract]
|
| 16.
|
Mazzoni, M. C.,
Borgstrom, P.,
Warnke, K. C.,
Skalak, T. C.,
Intaglietta, M.,
and Arfors, K. E.
(1995)
Int. J. Microcirc. Clin. Exp.
15,
265-270[Medline]
[Order article via Infotrieve]
|
| 17.
|
Ward, B. J.,
and Firth, J. A.
(1989)
J. Mol. Cell. Cardiol.
12,
1337-1347
|
| 18.
|
Giese, H.,
Mertsch, K.,
and Blasig, I. E.
(1995)
Neurosci. Lett.
191,
169-172[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Mertsch, K.,
Grune, T.,
Siems, W. G.,
Ladhoff, A.,
Saupe, N.,
and Blasig, I. E.
(1995)
Cell. Mol. Biol. Res.
41,
243-253
|
| 20.
|
Watsky, M. A.,
Cooper, K.,
and Rae, J. L.
(1992)
J. Membr. Biol.
128,
123-132[Medline]
[Order article via Infotrieve]
|
| 21.
|
Roeper, R.,
Lorra, C.,
and Pongs, O.
(1997)
J. Neurosci.
17,
3379-3391[Abstract/Free Full Text]
|
| 22.
|
Tessier, S.,
Karczewski, P.,
Krause, E-G.,
Pansard, Y.,
Acar, C.,
Lang-Lazdunski, M.,
Mercadier, J-J.,
and Hatem, S. N.
(1999)
Circ. Res.
85,
810-819[Abstract/Free Full Text]
|
| 23.
|
Koh, S. D.,
Perrino, B. A.,
Hatton, W. J.,
Kenyon, J. L.,
and Sanders, K. M.
(1999)
J. Physiol. (Lond.)
517,
75-84[Abstract/Free Full Text]
|
| 24.
|
Braun, A.,
and Schulman, H.
(1995)
Annu. Rev. Physiol.
57,
417-445[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Borbiev, T.,
Verin, A. D.,
Shi, S.,
Liu, F.,
and Garcia, J. G. N.
(2001)
Am. J. Physiol.
280,
L983-990
|
| 26.
|
Cai, H.,
Davis, M. E.,
Drummond, G. R.,
and Harrison, D. G.
(2001)
Arterioscler. Thromb. Vasc. Biol.
21,
1571-1576[Abstract/Free Full Text]
|
| 27.
|
Flemming, I.,
Fisslthaler, B.,
Dimmeler, S.,
Kemp, B. E.,
and Busse, R.
(2001)
Circ. Res.
88,
E68-75[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Mertsch, K.,
Grune, T.,
Kunstmann, S.,
Wiesner, B.,
Ladhoff, A. M.,
Siems, W. G.,
Haseloff, R. F.,
and Blasig, I. E.
(1998)
Biochem. Pharmacol.
56,
945-954[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Hoch, B.,
Haase, H.,
Schulze, W.,
Hagemann, D.,
Morano, I.,
Krause, E. G.,
and Karczewski, P.
(1998)
J. Cell. Biochem.
68,
259-268[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Blasig, I. E.,
Giese, H.,
Schroeter, M. L.,
Sporbert, A.,
Utepbergenov, D. I.,
Buchwalow, I. B.,
Neubert, K.,
Schönfelder, G.,
Freyer, D.,
Schimke, I.,
Siems, W-E.,
Paul, M.,
Haseloff, R. F.,
and Blasig, R.
(2001)
Microvasc. Res.
62,
114-127[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Schroeter, M. L.,
Müller, S.,
Lindenau, J.,
Wiesner, B.,
Hanisch, U. K.,
Wolf, G.,
and Blasig, I. E.
(2001)
Neuroreport
12,
2513-2517[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Kingston, R. E.,
Chomczynski, P.,
and Sacchi, N.
(1994)
in
Curr. Protocols in Mol. Biol.
(Ausubee, F. M.
, Brent, R.
, Kingston, R. E.
, Moore, D. D.
, Seidman, J. G.
, Smith, d. A.
, and Struhl, K., eds), Vol. 1
, pp. 4.2.1-4.2.7, John Wiley & Sons, New York
|
| 33.
|
Hoch, B.,
Wobus, A. M.,
Krause, E. G.,
and Karczewski, P.
(2000)
J. Cell. Biochem.
79,
293-300[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Lowry, O. H.,
Rosenbrough, N. J.,
Farr, A. L.,
and Randall, R. J.
(1951)
J. Biol. Chem.
193,
265-275[Free Full Text]
|
| 35.
|
Uese, K.,
Hagiwara, N.,
Miyawaki, T.,
and Kasanuki, H.
(1999)
J. Mol. Cell. Cardiol.
31,
1975-1984[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Wang, H-S.,
Pan, Z.,
Shi, W.,
Brown, B. S.,
Wymore, R. S.,
Cohen, I. S.,
Dixon, J. E.,
and McKinnon, D.
(1998)
Science
282,
1890-1893[Abstract/Free Full Text]
|
| 37.
|
Tobimatsu, T.,
and Fujisawa, H.
(1989)
J. Biol. Chem.
264,
17907-17912[Abstract/Free Full Text]
|
| 38.
|
Nghiem, P.,
Saati, S. M.,
Martens, C. L.,
Gardner, P.,
and Schulman, H.
(1993)
J. Biol. Chem.
268,
5471-5479[Abstract/Free Full Text]
|
| 39.
|
Mayer, P.,
Möhling, M,
Idlibe, D.,
and Pfeiffer, A.
(1995)
Basic Res. Cardiol.
90,
372-379[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Langheinrich, U.,
Mederos Schnitzler, M.,
and Daut, J.
(1998)
Eur. J. Physiol. (Pfluegers Arch.)
435,
435-438
|
| 41.
|
Jovanovic, S.,
and Jovanovic, A.
(2001)
Int. J. Mol. Med.
7,
639-643[Medline]
[Order article via Infotrieve]
|
| 42.
|
Cannell, M. B.,
and Sage, S. O.
(1989)
J. Physiol. (Lond.)
419,
555-568[Abstract/Free Full Text]
|
| 43.
|
Hoshi, T.,
Zagotta, W. N.,
and Aldrich, R. W.
(1991)
Neuron
7,
547-556[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Schulman, H.
(1995)
Curr. Opin. Neurobiol.
5,
375-381[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Ledoux, J.,
Chartier, D.,
and Leblanc, N.
(1998)
J. Pharmacol. Exp. Ther.
290,
1165-1174
|
| 46.
|
Arnould, T.,
Michiels, C.,
Alexandre, I.,
and Remacle, J.
(1992)
J. Cell. Physiol.
152,
215-221[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Ikeda, M.,
Ariyoshi, H.,
Sakon, M.,
Kambayashi, J.,
Yoshikawa, N.,
Shinoki, N.,
Kawasaki, T.,
and Monden, M.
(1998)
Cell Calcium
24,
49-57[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Srinavasan, M.,
Edamn, C. F.,
and Schulman, H.
(1994)
J. Cell Biol.
126,
839-852[Abstract/Free Full Text]
|
| 49.
|
Hagemann, D.,
Hoch, B.,
Krause, E. G.,
and Karczewski, P.
(1999)
J. Cell. Biochem.
74,
202-210[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Singer, H. A.,
Benscoter, H. A.,
and Schworer, C. M.
(1997)
J. Biol. Chem.
272,
9393-9400[Abstract/Free Full Text]
|
| 51.
| |